The Russian market for fillers and biorevitalisants continues to expand rapidly. In the first quarter of 2026, it reached 10.8 billion roubles, a 35.5% increase compared with the same period a year earlier, GxP News reports. At the same time, a qualitative shift has been underway in recent years: the budget category is shrinking while demand moves toward expensive multi-component formulations. According to RNC Pharma, the share of products costing more than 20,000 roubles has nearly doubled over the past four years, rising from 12.3% to 21.6%.
Meanwhile, the share of injectable products priced below 5,000 roubles fell to 7.8% in the first quarter of 2026, down from 11.8% in 2022, the analysts said. The 5,000–10,000 rouble segment also lost ground, dropping to 21.3%. Drugs priced between 10,000 and 20,000 roubles per pack continue to dominate, accounting for more than 49.3% of total retail sales in value terms during the period.
As an example of a successful premium hybrid cosmetic product, the analysts cited Yuveluk from South Korea’s Veim, which entered the Russian market in 2023. Last year, the product’s rouble sales volume grew 80-fold compared with 2024. A notable example of import substitution, they said, is Biogel, a brand developed at the Skolkovo technopark. Although the product is relatively new, it broke into the top ten brands in the first quarter of 2026 and captured nearly 4% of all rouble sales in the segment.
Also noteworthy was the 2023 market entry of Ellagen, a domestic product from Aptos. The manufacturer launched a collagen stimulator with a high (80%) concentration of poly-L-lactic acid (PLLA). While the product currently holds a modest share of the overall market, it already accounts for more than 15% of rouble sales in the PLLA category.
In terms of physical volume, demand in the first quarter of 2026 rose by 22.8% in minimum dosage units to 1.71 million, the analysts said. In pack terms, growth was 25.8% to 1.1 million packs. The trend continued the momentum of a record-breaking 2025, when the market sold 6.34 million units (+10.4%) worth 38.6 billion roubles (+34.5%), the largest value increase in three years.
More than 1,300 product items — representing over 200 brands — were available on the market last year, GxP News reports. In terms of sales value, Merz Pharma’s Belotero line led the market with a 9.3% share in the first quarter of 2026. The brand’s sales rose 22% in roubles and 10% in packs compared with January–March 2025.
The departure of foreign manufacturers from the injectable cosmetics market has triggered a transformation of the segment, GxP News concludes. Russian companies are filling the vacated niches, offering doctors and patients modern products and demonstrating technological progress.
